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Abstract
Knowledge of protein domains that function as the biological effectors for diverse post-translational modifications of
histones is critical for understanding how nuclear and epigenetic programs are established. Indeed, mutations of chromatin
effector domains found within several proteins are associated with multiple human pathologies, including cancer and
immunodeficiency syndromes. To date, relatively few effector domains have been identified in comparison to the number
of modifications present on histone and non-histone proteins. Here we describe the generation and application of human
modified peptide microarrays as a platform for high-throughput discovery of chromatin effectors and for epitope-specificity
analysis of antibodies commonly utilized in chromatin research. Screening with a library containing a majority of the Royal
Family domains present in the human proteome led to the discovery of TDRD7, JMJ2C, and MPP8 as three new modified
histone-binding proteins. Thus, we propose that peptide microarray methodologies are a powerful new tool for elucidating
molecular interactions at chromatin.
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Introduction
Chromatin structural dynamics regulate diverse cellular func-
tions that influence survival, growth, and proliferation. Disruption
of chromatin homeostasis is thought to fundamentally impact on
the development and progression of cancers and other diseases.
One of the major mechanisms for regulating chromatin structure
involves the reversible covalent post-translational modification
(PTM) of histone proteins by chemical moieties such as acetyl-,
methyl- and phospho- groups. These chemical marks are proposed
to constitute an epigenetic code that can be maintained in dividing
cells and inherited across generations. Combinations of different
histone modifications are linked to discrete chromatin states and
are thought to regulate the accessibility of DNA to transacting
factors [1,2]. At the molecular level, histone marks can act as
ligands for modular protein domains found on chromatin-
regulatory proteins [3,4]. In this context, the proteins and domains
that recognize histone modifications, named ‘‘effectors’’ or
‘‘readers’’, are thought to define the functional consequences of
many classes of modifications by transducing molecular events at
chromatin into biological outcomes.
Critical insight into how domain recognition for histone
modifications influences chromatin activities has come from the
identification and characterization of methyl-lysine effectors.
Because methylation does not neutralize the charge of the
modified residue nor does addition of methyl groups add
considerable bulk, this mark is believed to create a distinct
molecular architecture on histones that is then recognized by
specialized binding domains (e.g. chromodomains (CD) and Plant
Homeodomain (PHD) fingers) present within chromatin-regulato-
ry proteins. For example, components of repressive complexes,
such as heterochromatin protein 1 (HP1), contain CDs that allows
them to specifically recognize the appropriate repressive methyl-
ation mark, histone H3 trimethylated at lysine 9 (H3K9me3).
Similarly, histone H3 trimethylated at lysine 4 (H3K4me3), which
is postulated to enhance transcriptional activation due to its
enrichment near the transcriptional start site of active genes [5–7],
is recognized by several modules found on factors associated with
transcriptional activation [8,9]. However, H3K4me3 is also a
ligand for complexes with very different activities, such as
transcriptional repression [10] and recombination [11,12]. Taken
together, the biological outcomes of histone marks are impacted by
both their location in chromatin regions and the repertoire of
effectors that have access to those regions. While several effector
modules have been discovered for H3K4me3 and H3K9me3,
many other marks have few or no known effectors. Since
characterization of effector domain interactions with histone
state-specific ligands has been instrumental in unraveling
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6789chromatin-signaling networks, it is important to develop new
methods that allow for a systematic, high-throughput way to
identify novel histone mark sensors.
Here we describe the development, validation, and application
of a human epigenome peptide microarray platform (HEMP) for
high-throughput identification of ligands for effector modules. We
have probed this platform with modification-specific antibodies
and known chromatin effector domains to test the integrity of the
individual peptide features on the slides. Furthermore, we screened
a large library of Royal Domain family members and identified
three modules (the chromodomain of MPP8 (MPP8CD) and the
tudor domains (TD) of TDRD7 (TDRD7TD), and JMJ2C
(JMJ2CTD)) with novel modified-histone binding activity. Taken
together, our results demonstrate that the technology platform
described here can, broadly, contribute to the unraveling of
epigenetic mechanisms and, more specifically, facilitate molecular
dissection of chromatin signaling networks.
Results
Human epigenome peptide array construction and
validation
To generate HEMP as a tool for characterization and discovery of
chromatin effectors, we first synthesized a large collection of
biotinylated histone peptides of approximately 20 amino acids in
length. The peptides correspond to regions of human histone proteins
that are either unmodified or contain a single modification (acetyl-,
methyl-, or phosphoryl- moieties) at known PTM sites (Table S1).
The quality of all the peptides used in the study was confirmed by
mass spectrometry and dot-blot analyses (data not shown). Notably,
the majority of lysine residues known to be methylated or acetylated
on histones in humans are represented in this library, including all
methyl-lysine states detected to date on histone H3. The modified
peptide features were spotted onto streptavidin-coated slides,
incubated with an antibody or effector domain of interest, and then
theantibodyoreffectordomainwasvisualizedasschematized(Fig.1).
Peptides were secured to slides by biotin-streptavidin interactions
rather than other types of slide surfaces to direct the orientation of
peptides and to provide sufficient space from the surface to allow for
ligand-recognition (data not shown).
First HEMP arrays were probed with a number of commercially
available antibodies commonly used in the literature to validate the
integrity of the spotted peptides (Table S2). We chose antibodies
that represent the different classes of modifications present on the
array (lysine and arginine methylation, phosphorylation, and
acetylation). As shown in Figure 2a, the peptide detected upon
array probing was consistent with the epitope specificity designated
in the product data sheets provided with the various antibodies. For
example a cH2AX antibody bound specifically to H2AX peptides
(residues 121–142) phosphorylated on Ser139, but the antibody did
not significantly recognize the unmodified H2AX peptide or the
other sixty peptides spotted on the array (Fig. 2a(iv)). Similarly,
antibodies raised against monomethylated H3K9 (Fig. 2a(i)),
asymmetric dimethylated H3R2 (Fig. 2a(ii)), trimethylated H4K20
(Fig. 2a(v)), and acetylated H3K18 (Fig. 2a(iii)) detected most
strongly theappropriate peptides without appreciably cross-reacting
with other peptides present on the HEMP slide. Based on these
data, we conclude that the printing of the peptides onto slides as
such does not disrupt peptide integrity since several independent
epitopes are adequately recognized by a number of antibodies.
To facilitate a quantitative interpretation of array data, for
instance for factors (antibodies and protein modules) that recognize
more than one epitope, we utilized heatmap representations
(Fig. 2b), which have been widely used for the presentation of
nucleotide array data. Peptide array data was converted into
heatmaps by determining the signal-to-noise ratio (SNR) at all
features, with the values range-normalized (range 0–100) to address
intrinsic variations in antibody affinities (see methods). As an
example, an acetyl-lysine antibody was probed on our platform to
determine the relative affinity of this antibody for the fourteen
acetylated histone peptides present on the arrays. As shown in
Figure 2b, this antibody, while detecting a broad spectrum of
acetylated residues, preferentially recognizes acetyl-lysines present
on histone H4 in comparison to acetyl-lysines found on H2A, H2B,
or H3. Analyzing peptide array data in heatmap-form additionally
allows for quick assessment of antibody cross-reactivity. For
example, an antibody raised against a H3K79me3 antigen that is
documented to recognize both H3K79me3 and H3K79me2,
detects both H3K79me3 and H3K79me2 peptides when tested
on HEMP slides (Fig. 2b). Inspection of the heatmap, however,
indicates that the two epitopes are not recognized equally; a
stronger signal is observed with H3K79me3 peptides relative to
H3K79me2, and H3K79me1 is not detected (Fig. 2b). Appropriate
interpretation of many techniques in chromatin biology – such as
chromatin immunoprecipitation (ChIP) assays, relies on the
availability of highly specific antibodies. Our data demonstrate
the utility of using HEMP arrays as a tool to obtain a
comprehensive, unbiased assessment of the relative specificities of
newly developed antibodies prior to their use in downstream
applications.
Detection of modification-dependent binding activity by
known methyl-lysine effector modules
Next, we probed slides with protein modules that have known
methyl-lysine binding activity. As shown in Figure 3a, the CD of
Drosophila melanogaster heterochromatin protein 1 (HP1) alpha, the
PHD finger of human inhibitor of growth 3 (ING3), and the
double CDs of human Chromodomain-helicase-DNA-binding
protein 1 (CHD1) all bind to their cognate histone ligand.
Although this assay cannot be used to measure kinetic parameters,
a comparison of interaction intensities detected on peptide arrays
with published dissociation constants between several effectors and
various histone ligands, a general pattern emerges suggesting that
interactions that are #150–300 uM Kd range can be detected on
the arrays (Fig. 3; Table S3; data not shown). Even though weak
interactions will not be discerned (Kd . 300 uM), we conclude
that this technology is suitable for proteomic-scale identification of
most physiologically relevant protein PTM sensors, since virtually
all published effector-PTM interactions are within the detection
limit of HEMP technology.
High-throughput identification of novel methyl-lysine
effector modules
In previous work we demonstrated the ability of pilot versions of
the peptide microarray platform to identify novel ligands for a
number of specific protein modules [11,13–15]. To test the
contemporary HEMP slides in a proteome-wide discovery context,
we generated an expression library of chromatin-associated
domains consisting primarily ofRoyal super-family members (Table
S4). The Royal super-family, defined by conservation of sequence
and structural elements, includes CDs, TDs, MBT (malignant brain
tumor)repeats, plantAgenet, andPWWPdomains [16].Withinthis
family, there are a number of established methyl-lysine and methyl-
arginine effector domains. Further, it is likely that amongst the
numerous uncharacterized members of the family, new effectors
await discovery. Therefore, we reasoned that the Royal family –
consisting of known and candidate effectors modules, is a promising
Royal Family Chromatin Binding
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6789Figure 1. Key steps in the human epigenome peptide microarray (HEMP) procedure.
doi:10.1371/journal.pone.0006789.g001
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PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6789Figure 2. HEMP slides as a diagnostic tool for testing antibody specificity. (a) Array images for antibodies: i) anti-H3K9me1, ii) anti-H3R2me2
(asymmetric), iii) anti-H3K18ac, iv) anti-cH2AX, and v) anti-H3K20me3 with schematic of array layout and key. (b) Heatmap representation of antibody
HEMP slide data (See Table S2 for additional antibody details). The epitope(s) that the antibody was generated against is/are highlighted with a white
border. See ‘‘Heatmap PTM key’’ for details about peptides with post-translational modifications (PTMs). Note, that di-methyl arginine residues with
blue circles are symmetrically di-methylated. SNR RN, signal-to-noise ratio range-normalized. n.t., not tested.
doi:10.1371/journal.pone.0006789.g002
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of BRK, MRG, and SWIRM domains found in the human
proteome were included in our screen because these motifs are
commonly co-present with Royal family domain-containing
chromatin-associated proteins. We used two additional criteria for
testing specific domains included in the expression library: (i)
domains with known binding activity to serve as positive controls
and (ii) domains found on proteins that are implicated in human
disease. To this end, we tested approximately seventy distinct
domains, including the majority of the Royal family members
present in the human proteome (Fig. 4). As summarized in
Figure 4a, a large majority of chromodomains (25/32) was
screened, and out of these, eight positives were detected – seven
of which had previously been described [17–21], and one novel
interaction for the protein MPP8 was discovered (Fig. 4b(i); Table 1;
see below). We failed to detect association of the MRG15CD with
H3K36me [22], though we note that there are alternatively spliced
forms of this domainthat might havedifferentactivity. Similarly, we
tested a version of CDYL1CD that bound to H3K9me3 in vitro,i n
contrast to a differentially spliced version that was reported to bind
weakly [23] (Fig. 4c). Next we tested for co-localization of the full-
length CDYL1 protein (harboring the version of the CD tested in
our library) with histone marks in vivo (Fig. 4d). These localization
experiments support our in vitro data since CDYL1 co-localizes with
H3K9me3, but not H3K4me3. Taken together, 25% of chromo-
domains in the human proteome have clearly detectable histone
methyl-lysine binding activity. The remaining majority (75%) of
human chromodomains might only recognize histone PTMs in the
context of nucleosomes and thus would not be detected on peptide
arrays. Orthese CDsmayhave altogether different activities such as
recognition of a methylated non-histone protein or a different non-
histone molecular ligand like RNA [24] (see discussion).
Twenty of twenty-nine tudor domains present in the human
proteome were also investigated (Fig. 4a; Table 1). Within this
group were three known methyl-lysine-binding TDs (53BP1,
PHF20, and JMJ2A [25–27]) as well as a TD with binding
specificity for non-histone arginine methylated substrates (SMN
[26,28]). Accordingly, 53BP1, PHF20, and JMJ2A bound to their
known ligands, while SMN did not bind any of the methyl-histone
peptides – including arginine methylated peptides (Table 1). Of
the sixteen uncharacterized tudor domains, we observed that two
new tudor domains (TDRD7 and JMJ2C) have methyl-histone
binding activity (Fig 4b; see below). We also tested several
additional domains, including MRG, BRK, SWIRM, and PWWP
domains, but no binding was detected. Thus, 25% of the tudor
domains in our library have histone methyl-lysine binding activity,
and several other domains did not have detectable histone peptide
binding when tested with HEMP technology.
Validation of candidate positives
Next, we investigated whether the novel interactions discovered
in the screen could also be detected in conventional modified-
histone binding assays. First, in biotinylated histone peptide pull-
down assays, MPP8CD, TDRD7TD, and JMJ2CTD, all reproduced
the binding activity observed in the screen (Fig. 4c). Second, GST-
pull-down assays of purified bulk histones, GST-MPP8CD, GST-
TDRD7TD, and GST-JMJ2CTD proteins all pellet full-length
histone H3, but GST does not (Fig. 4e). Moreover, we detected the
cognate modification bound by each respective domain in the
pellet – for example, JMJ2CTD preferentially purified H3K4me3
versus H3K9me3 and TDRD7TD preferentially pellets H3K9me3
(Fig. 4e). Finally, we found that MPP8CD associates with
nucleosomes purified from HeLa cells, preferentially interacting
with nucleosomes enriched for H3K9me3 but not H3K4me3
(Fig. 4f; for quantification see Fig. S1). We note that due to
homology to the CDY family, Fischle et al. suggested that
MPP8CD, might bind to the ARK(S/T) motifs present around the
H3K9 and H3K27 methylation sites [23] and although we did not
detect an interaction with H3K27me on arrays, this interaction is
observed in other in vitro binding assays (Fig. S2). Taken together,
our results argue that MPP8CD, TDRD7TD, and JMJ2CTD
represent three new domains with specific histone PTM-binding
activity and that HEMP technology can be used to identify and
easily validate novel chromatin effectors.
Discussion
Previously we demonstrated the utility of a modified histone
peptide microarray to characterize methyl-lysine effector functions
for the PHD fingers present within the yeast proteome [13]. Here
we describe a human epigenome peptide microarray platform as a
high-throughput tool for discovery of the factors that sense
chromatin modifications. We focused our screen on the Royal
domain super-family, testing greater than fifty domains from the
chromodomain, PWWP, and Tudor families, as well as the
majority of BRK, MRG, and SWIRM domains for binding to
Figure 3. Detection of known chromatin effector-histone PTM interactions using HEMP slides. (a) The chromodomain of Drosophila
melanogaster heterochromatin protein 1 alpha (dsHP1CD), (b) the plant homeodomain of human inhibitor of growth 3 (ING3PHD), and (c) the double
chromodomains of human chromodomain-helicase-DNA-binding protein 1 (CHD1CD), all recognize, as indicated, their cognate histone ligand on the
peptide array. All these protein domains are expressed as GST-fusions and an array probed with GST alone (d) serves as a negative control. For order
of peptide spotting, see schematic in Figure 2a.
doi:10.1371/journal.pone.0006789.g003
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PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6789Figure 4. Identification of three novel methyl-histone binding modules. (a) Table summarizing the number of domains tested in this study
and the number of interactions detected. CD, chromodomain. TD, tudor domain. (b) Array images for: i) MPP8CD, ii) TDRD7TD, and iii) JMJ2CTD.
Peptide/s detected in each experiment is indicated. See Figure 2a for array schematic. (c) Validation of array results in peptide-binding assays.
Biotinylated peptide pull-down assay using peptides detected in (b) and the indicated GST-fusion proteins. (d) Co-localization of CDYL1 with
H3K9me3. Representative immunofluorescence images of U2OS cells transfected with His-tagged CDYL1 and co-stained with the indicated
antibodies. K9 = H3K9me3, K4 = H3K4me3. (e) Validation of array results in bulk-histone binding assays. Calf-thymus histone pull-down with the
indicated proteins: MPP8CD, TDRD7TD, and JMJ2CTD. In each case the domain was pulled-down and the pellet was probed with the indicated
antibodies. (f) MPP8CD binds to HeLa-purified nucleosomes enriched for H3K9me3 but not H3K4me3. Pull-downs of GST or GST-MPP8CD protein after
incubation with HeLa nucleosomes were probed with the antibodies indicated (see Fig. S1 for quantitation).
doi:10.1371/journal.pone.0006789.g004
Royal Family Chromatin Binding
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present on chromatin-associated human proteins. In our screen we
detected the ten known modified-histone binders present in the
library (CHD1CD, CDY1 CD, CDYL1 CD, CDYL2 CD, HP1a CD,
HP1bCD, HP1cCD, 53BP1 TD, PHF20TD and JMJ2A TD) and
discovered three novel methyl-histones binding modules:
MPP8CD, TDRD7TD, and JMJ2CTD (Table 1). We performed
various histone-binding assays to independently validate the new
interactions identified in the screen (Fig. 4c,e,f). Based on sequence
alignment, MPP8CD, TDRD7TD, and JMJ2CTD all appear to
harbor a hydrophobic cage, the conserved molecular strategy for
recognizing methyl-lysine (Fig. S3). Interestingly, TDRD7TD is the
first tudor domain described to date that preferentially binds to
H3K9me2/3 versus the numerous other methyl-lysine sites on the
arrays. Examination of the sequence reveals that the TDRD7TD
contains conserved sequence with other tudor domains at the
residues that comprise the hydrophobic cage (Fig. S3a; highlighted
with a green circle), but lacks the residue critical for H3K4me site
specificity found in both JMJ2C and JMJ2A (Fig. S3a; highlighted
with an orange circle). JMJ2C, which was identified here as an
H3K4me-binder, functions as a histone lysine demethylase that
removes one or more methyl moieties from H3K9me3 and
H3K36me3 [27,29], and its ability to bind to H3K4me might be
important for regulating the dynamics of these other histone
marks. The function of TDRD7 and the role of H3K9me-binding
are not yet known and require future investigation.
Besides the positive interactions detected in the screen, we can
also draw conclusions based on the modules that do not interact
with any of the peptides present on the array. In this regard, there
are several explanations as to why a domain may fail to give
detectable signal on the HEMP array – the simplest explanation
being that the ligand for the domain is not present on the slide (e.g.
SMNTD). Additionally, it is possible that ligand-recognition by a
candidate domain might only occur in the context of a nucleosome
or require multiple modifications present within the ligand. Since
HEMP is a versatile platform, meaning the peptide composition
can be altered as new chromatin PTMs are discovered, peptides
corresponding to new modifications can be easily synthesized and
incorporated. This technique is also well-suited to study the
combinatorial nature of chromatin modifications, since peptides
can be produced with more than one modification [30]. While the
peptide library generated here contains human histone sequences
(Table S1) there are occasional differences in the primary amino
acid structure of histones between organisms, so this technology
can be adapted to study modification-dependent interactions in
other organisms. Moreover, lysine methyl-transferases are evolu-
tionarily conserved with more than 50 candidates in the human
proteome – and it is probable that lysine methylation of non-
histone proteins will emerge as a common mechanism for
regulating signaling networks. For example, multiple lysine PTM
sites contribute to various activities of p53 [31–33], and it is
possible that novel binding partners for PTMs of p53 and other
proteins in diverse organisms can be identified using array
methods as described here.
Finally, in addition to the Royal family, there are several other
domain families in which a subset of members is reported to have
chromatin-effector functions. For example, the interaction be-
tween several PHD fingers and histones is regulated by lysine
methylation [8–11,15,34,35]. The ankryin repeats of G9A and
GLP have also been shown to bind H3K9me [36]. As there are
150–300 PHD fingers and .300 ankryin repeats in the human
proteome, HEMP technology can provide a rapid and reliable
method for discerning potential chromatin effector functions for
these modules. Moreover, the relative ease of diversifying the
HEMP arrays to include additional modified peptides, dual-
modified peptides, and non-histone modified peptides (e.g. methyl-
lysine p53), will allow for the testing of numerous protein libraries,
thus paving the way to discovery of domains with as yet to be
defined activity. In summary, we have established array platforms
for proteomic-scale discovery of the proteins that sense and
transduce chromatin states into diverse biological readouts.
Materials and Methods
Human epigenetic peptide arrays
Biotinylated histone peptides were synthesized as described
previously [10]. Peptides were printed in six replicates onto
streptavidin-coated slides (ArrayIt) using the VersArray Compact
Microarrayer (BioRad). All printed slides were air-dried overnight
prior to use. Directly before use, unbound streptavidin sites were
Table 1. Modification-dependent interactions detected using HEMP arrays.
Protein Domain H3K4me H3K9me H3K27me H4K20me Reference
CHD1 CD + 22 2 [21,38]
CDY1 CD 2 ++ 2 [23,26]
CDYL1 CD ++ 2 [23,39]
CDYL2 CD 2 ++ 2 [23]
HP1a CD 2 + 22 [17,18]
HP1b CD 2 + 22 [26]
HP1c CD 2 + 22 [26]
MPP8 CD 2 + 22 This study
53BP1 TD 222 + [25,26]
JMJ2A TD + 22 + [26,27]
JMJ2C TD + 22 2 This study
PHF20 TD 222 + [26]
TDRD7 TD 2 + 22 This study
CD = chromodomain; TD = tudor domain.
doi:10.1371/journal.pone.0006789.t001
Royal Family Chromatin Binding
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at 4uC overnight with GST-fusion proteins diluted in peptide
binding buffer (50 mM Tris-HCl 7.5, 150 mM NaCl, 0.1% NP-
40, 20% fetal bovine serum). Next, slides were washed 6 times with
peptide binding buffer and probed with anti-GST antibody
(Millipore) diluted in PBS containing 0.1% Tween-20 (PBST)
and 20% FBS at room temperature for 1 hour. Slides were washed
with PBST six times, then incubated 30 minutes with Alexa Fluor
647 chicken anti-rabbit IgG (Invitrogen) diluted in (PBST with
20% FBS). Lastly, slides were washed with PBST 6 times, briefly
rinsed with PBS and air-dried. A GenePix 4000 scanner
(Molecular Devices) was used to scan the arrays, and data images
were analyzed by GenePix Pro Version 56.0 1 software.
Heatmap analysis
To generate a heatmap representation of the data, the SNR
(signal to noise ratio) column was first taken from the GPR
(GenePix Report) files generated upon image analysis. GenePix
6.1 calculates SNR as the ratio of the mean net signal intensity
(mean background pixel intensity subtracted from the mean
foreground pixel intensity) over the standard deviation of the
background pixel intensity. Because each antibody performs
differently with respect to binding specificity on the array, the
SNR for each array was normalized to a range of 0–100. These
numbers were then converted to a heatmap with Java TreeView
1.13, with the peptides listed by row and the columns listed by
antibody.
Pull-down assays
Biotinylated histone pull-down assays were performed as
performed previously [10]. Briefly, 1 ug of biotinylated peptides
were incubated with 1 ug of GST-domain in peptide binding
buffer (50 mM Tris-HCL, pH 7.5, 150 mM NaCl, 0.1% Non-
idetP-40) overnight at 4uC. After 1 h incubation with streptavidin
beads (Amersham), complexes were washed 3 times with binding
buffer, and the bound proteins were subjected to western analysis.
Calf thymus (CT) histone pull-down and assays were performed as
in [10]. Briefly, 10 ug of GST-domain was incubated with 50 mg
CT histones (Worthington) in binding buffer (50 mM Tris-HCL,
pH 7.5, 1 M NaCl, 1% NonidetP-40). After 1 h incubation with
glutathione beads (Amersham), complexes were washed 3 times
with binding buffer, and the bound proteins were subjected to
western analysis. HeLa nucleosome pull-down assays were
performed as reported in [15]. Briefly, 10 ug of GST-domain
was incubated with 10 ug of purified HeLa nucleosomes in
binding buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% NP-40,
10% glycerol). Incubation with glutathione beads and wash steps
were the same as for CT histone pull-downs.
Construction of chromatin domain expression library
Sequences were amplified from human cDNA and inserted into
pDONR221. The sequence validated clones where subsequently
subcloned into pDEST15 (Invitrogen). Domain boundaries were
chosen based on SMART database entries [37] (see Table S4).
Supporting Information
Figure S1 Quantitation of histone marks in HeLa nucleosomes
pelleted by MPP8CD. ImageJ software was used for quantitative
densitometric analysis of the gel band intensities shown in
Figure 4f. For each antibody the pellet/input was calculated and
plotted as a percentage.
Found at: doi:10.1371/journal.pone.0006789.s001 (0.07 MB
DOC)
Figure S2 In vitro association of MPP8CD with H3K27me. (a)
Histone peptide pull-downs indicate weak association with the
chromodomain of MPP8 (MPP8CD) and H3K27me2/3. (b) Calf
thymus histone (CTH) pull-down assay (top) and HeLa nucleo-
some pull-down assay (bottom) probed with H3K27me3. MPP8CD
precipitates H3K27me3 from HeLa nucleosomes but not CTH.
Although we did not detect an interaction with H3K27me on the
array, we performed additional in vitro binding assays as a result of
a recent study [23] in which Fischle et al. suggest that CDs like the
one present in MPP8CD might bind ARK(S/T) motifs present at
both the H3K9 and H3K27 methylation sites. We note that the
binding of MPP8CD to H3K27me is weaker that H3K9me when
compared side-by-side in peptide pull-down assays.
Found at: doi:10.1371/journal.pone.0006789.s002 (0.28 MB
DOC)
Figure S3 Putative hydrophobic cage of MPP8, TDRD7, and
JMJ2C. (a) Alignment of tudor domains that bind methyl-lysine:
JMJ2A, JMJ2C, 53BP1, and TDRD7. An orange circle highlights
Asp945 of JMJ2ATD. #appears at residues that when mutated
diminish or ablate the H4K20me3-53BP1 tudor interaction [25]. *
marks residuesthat when mutated diminishorablatethe interaction
between the double tudor domain of JMJ2A with H3K4me3 [27].
(b) Alignment of chromodmains that bind H3K9me/27me: HP1,
CDY, and MPP8. #indicates residues that when mutated diminish
or ablate the interaction between the chromodomain of HP1 with
H3K9me [19]. (a) and (b) Residues shaded in yellow are highly
conserved in the region selected. A green circle marks residues that
compose the hydrophobic cage of (a) JMJ2A [27] or (b) HP1 [19].
Residues shaded in blue are identical in the selected region. All
sequences are those found in the human protein.
Found at: doi:10.1371/journal.pone.0006789.s003 (0.99 MB
DOC)
Table S1 HEMP Biotinylated Peptide library. Chemical mod-
ifications are indicated in parentheses after the modified residue.
The location of the biotin is indicated by (bio). ac = acetyl-, me =
methyl-, ph = phospho-
Found at: doi:10.1371/journal.pone.0006789.s004 (0.07 MB
DOC)
Table S2 Antibodies used to probe HEMP arrays.
Found at: doi:10.1371/journal.pone.0006789.s005 (0.03 MB
DOC)
Table S3 Comparison of histone marks detected on slide
platform to dissociation constants determined in independent
reports. CD = chromodomain; PHD = plant homeodomain;
TD = tudor domain.
Found at: doi:10.1371/journal.pone.0006789.s006 (0.08 MB
DOC)
Table S4 Expression library of domains tested in this study.
Found at: doi:10.1371/journal.pone.0006789.s007 (0.08 MB
DOC)
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